Focused Wealth Management Inc Has $4.55 Million Stock Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Focused Wealth Management Inc raised its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 3.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,165 shares of the exchange traded fund’s stock after acquiring an additional 1,087 shares during the quarter. SPDR S&P Biotech ETF comprises approximately 0.7% of Focused Wealth Management Inc’s holdings, making the stock its 22nd largest position. Focused Wealth Management Inc’s holdings in SPDR S&P Biotech ETF were worth $4,546,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pacifica Partners Inc. raised its position in shares of SPDR S&P Biotech ETF by 300.0% in the third quarter. Pacifica Partners Inc. now owns 200 shares of the exchange traded fund’s stock valued at $26,000 after purchasing an additional 150 shares during the period. GPS Wealth Strategies Group LLC raised its position in shares of SPDR S&P Biotech ETF by 197.3% in the second quarter. GPS Wealth Strategies Group LLC now owns 220 shares of the exchange traded fund’s stock valued at $30,000 after purchasing an additional 146 shares during the period. Atlas Capital Advisors LLC raised its position in shares of SPDR S&P Biotech ETF by 328.6% in the second quarter. Atlas Capital Advisors LLC now owns 300 shares of the exchange traded fund’s stock valued at $41,000 after purchasing an additional 230 shares during the period. Lumature Wealth Partners LLC bought a new position in shares of SPDR S&P Biotech ETF in the second quarter valued at approximately $47,000. Finally, TCI Wealth Advisors Inc. raised its position in shares of SPDR S&P Biotech ETF by 51.8% in the second quarter. TCI Wealth Advisors Inc. now owns 469 shares of the exchange traded fund’s stock valued at $64,000 after purchasing an additional 160 shares during the period.

NYSEARCA:XBI opened at $121.92 on Monday. SPDR S&P Biotech ETF has a 12 month low of $118.23 and a 12 month high of $174.79. The company’s 50 day moving average is $126.95 and its 200-day moving average is $128.50.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Read More: What is a stock buyback?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.